全文获取类型
收费全文 | 23343篇 |
免费 | 2484篇 |
国内免费 | 446篇 |
专业分类
耳鼻咽喉 | 153篇 |
儿科学 | 541篇 |
妇产科学 | 254篇 |
基础医学 | 2474篇 |
口腔科学 | 843篇 |
临床医学 | 2914篇 |
内科学 | 3975篇 |
皮肤病学 | 518篇 |
神经病学 | 1751篇 |
特种医学 | 445篇 |
外国民族医学 | 11篇 |
外科学 | 2059篇 |
综合类 | 2551篇 |
现状与发展 | 4篇 |
预防医学 | 2667篇 |
眼科学 | 1233篇 |
药学 | 1119篇 |
9篇 | |
中国医学 | 713篇 |
肿瘤学 | 2039篇 |
出版年
2024年 | 66篇 |
2023年 | 538篇 |
2022年 | 780篇 |
2021年 | 1208篇 |
2020年 | 1037篇 |
2019年 | 1062篇 |
2018年 | 997篇 |
2017年 | 1031篇 |
2016年 | 1013篇 |
2015年 | 1020篇 |
2014年 | 1495篇 |
2013年 | 1822篇 |
2012年 | 1223篇 |
2011年 | 1274篇 |
2010年 | 1072篇 |
2009年 | 1029篇 |
2008年 | 1016篇 |
2007年 | 1017篇 |
2006年 | 900篇 |
2005年 | 826篇 |
2004年 | 696篇 |
2003年 | 616篇 |
2002年 | 567篇 |
2001年 | 465篇 |
2000年 | 398篇 |
1999年 | 356篇 |
1998年 | 297篇 |
1997年 | 258篇 |
1996年 | 248篇 |
1995年 | 200篇 |
1994年 | 198篇 |
1993年 | 194篇 |
1992年 | 165篇 |
1991年 | 168篇 |
1990年 | 130篇 |
1989年 | 93篇 |
1988年 | 91篇 |
1987年 | 76篇 |
1986年 | 78篇 |
1985年 | 127篇 |
1984年 | 84篇 |
1983年 | 65篇 |
1982年 | 77篇 |
1981年 | 57篇 |
1980年 | 45篇 |
1979年 | 26篇 |
1978年 | 28篇 |
1977年 | 14篇 |
1976年 | 11篇 |
1975年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
《Clinical gastroenterology and hepatology》2022,20(5):1112-1121.e4
- Download : Download high-res image (419KB)
- Download : Download full-size image
13.
14.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
15.
16.
Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
17.
18.
Hyperhidrosis can seriously impair patients’ quality of life. Medical history, including heredity and hyperhidrosis during youth, as well as current age and time elapsed since menopause, is important to consider when distinguishing between postmenopausal hyperhidrosis and vasomotor symptoms to enable adequate treatment. This report concerns a subgroup of eight postmenopausal patients participating in a randomized controlled trial regarding botulinum toxin (Btx) type B treatment in craniofacial hyperhidrosis. Even though the sample size is small and the enrolment is not yet completed, the promising data collected hitherto are interesting to present in advance because this subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat. Patients were randomized to receive Btx type B or placebo. Measurements were performed before treatment and 3 ± 1 weeks after. The Dermatology Life Quality Index (DLQI) score was improved for all patients after Btx type B treatment (n = 3) with a median decrease of 9 points (90% median improvement). The placebo group (n = 5) had a median increase of 2 points (–18% median decline). When the same group (n = 5) received Btx type B (open) the DLQI score decreased with a median of 7 points compared with baseline (91% median improvement). Treatment‐related adverse events were temporary and did not prevent improvement of life quality. Furthermore, background data evaluation uncovered interesting findings regarding vasomotor symptoms in relation to postmenopausal hyperhidrosis. In conclusion, the results indicated that Btx type B seems to be a safe and effective treatment in postmenopausal craniofacial hyperhidrosis. Further research is encouraged. 相似文献
19.
《Journal of vascular and interventional radiology : JVIR》2020,31(4):630-634
PurposeTo retrospectively evaluate the safety and effectiveness of the Covera stent graft (SG) for the treatment of dysfunctional or thrombosed arteriovenous grafts (AVGs).Materials and MethodsWithin 29 months (February 2016–August 2018), 79 patients underwent Covera SG placement in the authors’ department for the treatment of dysfunctional AVGs. Data were available for 64 patients who underwent 64 procedures, using 64 devices. Minimum follow-up was 6 months, unless reintervention occurred. Mean follow-up was 277 days (6–923 days). Treatment characteristics were 51 cases with venous-graft anastomosis (VGA) stenosis (79.7%), 13 cases of puncture zone stenosis (20.3%), 14 cases of in SG stenosis (21.9%), 8 cases of pseudoaneurysm treatment (12.5%) (1 treatment area might have had more than 1 characteristic). Thirty-six patients presented with thrombosis (56.2%), and 31 of 64 case were de novo treatment areas (48.4%). Primary outcome measurements were technical success and post-intervention primary patency (PIPP) at 6 months, whereas secondary outcome measurements included factors influencing primary outcome.ResultsTechnical success was 100%. Median PIPP was 336 days, and 73.6% of treatment areas were patent at 6 months. There were no significant differences in terms of PIPP when de novo treatment areas were compared with restenotic areas (519 vs. 320 days, respectively; P = .1); patients who presented with versus those who presented without thrombosis (320 vs. 583 days, respectively; P = .07); puncture zone stenosis or elsewhere (329 vs. 686 days, respectively; P = .52); and VGA stenosis or elsewhere (336 vs. 335 days, respectively; P = .9).ConclusionsUse of the Covera SG for AVG treatment was safe and effective in every type of treatment area presented in this retrospective analysis. 相似文献
20.